<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Medical Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/medicine-technology-1/</link>
<description>Latest Medical Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2012. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/North-Shore-LIJ-Extends-Use-of-3rd-Party-Remote-Video-Auditing-into-ORs-33153-1/</link>
<pubDate>Tue, 21 May 2013 05:49:16 MST</pubDate>
<description><![CDATA[FOREST HILLS, N.Y.  , May 21, 2013 /-&#160;The North Shore-LIJ Health System is expanding a first-of-its-kind video monitoring system used to measure hand-washing compliance at North Shore University Hospital in   Manhasset, NY  , by introducing cameras in operating rooms at   Forest Hills   (NY) Hospital.   (Photo:  http://photos.prnewswire.com/prnh/20130521/NY17810 )   The new p... ]]></description>
</item>
<item>
<title><![CDATA[Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Vasomedical--Inc--To-Present-At-The-Second-Annual-Marcum-LLP-MicroCap-Conference-33152-1/</link>
<pubDate>Tue, 21 May 2013 05:49:04 MST</pubDate>
<description><![CDATA[WESTBURY, N.Y.  , May 21, 2013 /-&#160;Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, announced today that Dr.   Jun Ma  , President and CEO of Vasomedical, Inc. will present at the Second Annual Marcum LLP MicroCa... ]]></description>
</item>
<item>
<title><![CDATA[BioElectronics Presents FDA Reclassification Panel]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/BioElectronics-Presents-FDA-Reclassification-Panel-33151-1/</link>
<pubDate>Tue, 21 May 2013 05:48:51 MST</pubDate>
<description><![CDATA[FREDERICK, Md.  , May 21, 2013 /- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free consumer electronic devices, announced that CEO,   Andrew J. Whelan   is presenting today to the FDA's Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments for reclassifying the company's products for over the counter sales.   "I... ]]></description>
</item>
<item>
<title><![CDATA[Lehigh Valley Expands Fleet of Superbug-Slaying Robots]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Lehigh-Valley-Expands-Fleet-of-Superbug-Slaying-Robots-33150-1/</link>
<pubDate>Tue, 21 May 2013 05:48:38 MST</pubDate>
<description><![CDATA[ALLENTOWN, Pa.  , May 21, 2013 /-&#160;Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVC TM  devices, adding to its existing arsenal of five 5-foot-5 germ-killing UV disinfection robots. With seven devices taking up residence within the network, LVHN is now deploying the largest fleet of TRU-Ds in the U.S. to proactively combat superbugs an... ]]></description>
</item>
<item>
<title><![CDATA[Global Markets and Technologies for Optical Coherence Tomography (OCT)]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography--28OCT-29-33149-1/</link>
<pubDate>Tue, 21 May 2013 05:48:27 MST</pubDate>
<description><![CDATA[NEW YORK  , May 21, 2013 /- Reportlinker.com announces that a new market research report is available in its catalogue:   &#160;    Global Markets and Technologies for Optical Coherence Tomography (OCT)    http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&amp;utm_medium=pr&amp;utm_campaign=Medical_... ]]></description>
</item>
<item>
<title><![CDATA[New Data Validates CyberKnife SBRT for Prostate Cancer Treatment]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Data-Validates-CyberKnife-SBRT-for-Prostate-Cancer-Treatment-33148-1/</link>
<pubDate>Tue, 21 May 2013 05:48:19 MST</pubDate>
<description><![CDATA[SUNNYVALE, Calif.  , May 21, 2013 /-&#160; Accuray Incorporated  (Nasdaq:   ARAY ), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife&#174; Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). The study followed 304 patients for a median of 5 years, a... ]]></description>
</item>
<item>
<title><![CDATA[Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Sanofi-and-Regeneron-Announce-Publication-of-Positive-Phase-2a-Results-of-Dupilumab-in-Asthma-in-the-New-England-Journal-of-Medicine-33147-1/</link>
<pubDate>Tue, 21 May 2013 05:23:48 MST</pubDate>
<description><![CDATA[PARIS   and   TARRYTOWN, N.Y.  , May 21, 2013 /- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the  New England Journal of Medicine  published online the positive Phase 2a study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe allergic asthma. &#160;Dupilumab is an investigational monoclonal... ]]></description>
</item>
<item>
<title><![CDATA[Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Primary-Efficacy-and-Safety-Findings-from-Phase-3-Study-of-Janssens-Simeprevir-Administered-Once-Daily-Demonstrate-Sustained-Virologic-Response-in-Tre-33146-1/</link>
<pubDate>Tue, 21 May 2013 05:23:34 MST</pubDate>
<description><![CDATA[ORLANDO, Fla.  , May 21, 2013 /-&#160;Janssen R&amp;D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chroni... ]]></description>
</item>
<item>
<title><![CDATA[Frost &amp; Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Frost--26amp-3B-Sullivan-3A-BRIC-is-Not-Delivering-Promises-of-High-Growth-in-Healthcare-Markets-33145-1/</link>
<pubDate>Tue, 21 May 2013 05:06:02 MST</pubDate>
<description><![CDATA[MOUNTAIN VIEW, Calif.  , May 21, 2013 /-&#160;Healthcare organizations expanding into emerging markets like   Brazil  ,   Russia  ,   India   and   China   (BRIC) are realizing there are no shortcuts.&#160; This is proving particularly challenging, considering the current healthcare environment, especially in the United States.&#160; Companies must change the dialogue around BRIC,... ]]></description>
</item>
<item>
<title><![CDATA[Abaxis, Inc. to Present at the Stifel Annual Dental &amp; Veterinary Conference]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Abaxis--Inc--to-Present-at-the-Stifel-Annual-Dental--26amp-3B-Veterinary-Conference-33144-1/</link>
<pubDate>Tue, 21 May 2013 05:05:55 MST</pubDate>
<description><![CDATA[UNION CITY, Calif.  , May 21, 2013 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that   Martin Mulroy  , chief commercial officer , will present at the Stifel Annual Dental &amp; Veterinary Conference on Wednesday, May 29, 2013 at 11:30 a.m. ET. The conference will be held at Le Parker Meridien Hote... ]]></description>
</item>
<item>
<title><![CDATA[U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/U-S--Spending-on-Specialty-Medications-Likely-to-Increase-67-Percent-Through-2015-33143-1/</link>
<pubDate>Tue, 21 May 2013 05:05:48 MST</pubDate>
<description><![CDATA[ST. LOUIS  , May 21, 2013 /- U.S. spending on specialty prescription drugs &#8212; those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis &#8212; is projected to increase 67 percent by the end of 2015, according to a forecast released today by Express Scripts (NASDAQ: ESRX).    (Logo:  http://photos.prnewswire.com/prnh/20080827/EX... ]]></description>
</item>
<item>
<title><![CDATA[BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/BioRestorative-Therapies--Inc--to-Present-at-the-Marcum-MicroCap-Conference-33142-1/</link>
<pubDate>Tue, 21 May 2013 05:05:41 MST</pubDate>
<description><![CDATA[JUPITER, Fla.  , May 21, 2013 /-&#160;BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that   Mark Weinreb  , its President and CEO, will be presenting at the Marcum MicroCap Conference.&#160;&#160;    The conference will be held on Thursday,... ]]></description>
</item>
<item>
<title><![CDATA[Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market-33141-1/</link>
<pubDate>Tue, 21 May 2013 04:43:40 MST</pubDate>
<description><![CDATA[NEW YORK  , May 21, 2013 /- Reportlinker.com announces that a new market research report is available in its catalogue:   &#160;    Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market    http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&amp;utm_medium=... ]]></description>
</item>
<item>
<title><![CDATA[Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Ceregene-Reports-Additional-Efficacy-Data-From-Parkinsons-Disease-Phase-2b-Study-33140-1/</link>
<pubDate>Tue, 21 May 2013 04:43:31 MST</pubDate>
<description><![CDATA[SAN DIEGO  , May 21, 2013 /- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.&#160; This exploratory analysis identified a more robust res... ]]></description>
</item>
<item>
<title><![CDATA[Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Top-line-Data-Demonstrate-Primary-Endpoint-Achieved-in-Final-Pivotal-Phase-3-Study-of-Sufentanil-NanoTab-PCA-System-For-Management-of-Post-Operative-P-33139-1/</link>
<pubDate>Tue, 21 May 2013 04:43:21 MST</pubDate>
<description><![CDATA[REDWOOD CITY, Calif.  , May 21, 2013 /-&#160;AcelRx Pharmaceuticals, Inc. (Nasdaq:   ACRX ), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line data demonstrating that in a placebo-controlled Phase 3 study of its investigational sublingual Sufentanil... ]]></description>
</item>
<item>
<title><![CDATA[STAAR Surgical To Present At Upcoming Investor Conferences]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/STAAR-Surgical-To-Present-At-Upcoming-Investor-Conferences-33138-1/</link>
<pubDate>Tue, 21 May 2013 03:42:14 MST</pubDate>
<description><![CDATA[MONROVIA, Calif.  , May 21, 2013 /- STAAR Surgical Company (NASDAQ:   STAA ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it will participate in three upcoming investor conferences to review the Company's recent financial results and business developments with investors and interested parties.   STAAR Surgical will... ]]></description>
</item>
<item>
<title><![CDATA[North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/North-Carolina-Business-Owners-At-Risk-Because-Of-Defective-Medicare-Bidding-Program-33137-1/</link>
<pubDate>Tue, 21 May 2013 03:29:43 MST</pubDate>
<description><![CDATA[GASTONIA, N.C.   and   HENDERSONVILLE, N.C.  , May 21, 2013 /PRNewswire-USNewswire/ -- The controversial  Medicare bidding procurement program  for home medical equipment is forcing many small and large providers in   North Carolina   to lay off employees or close their businesses, developments that will likely disrupt the quality of service and products received by Medicare beneficiaries, say... ]]></description>
</item>
<item>
<title><![CDATA[RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/RxAlly-Releases-White-Paper-on-Necessity-of-Personalized-Pharmacist-Care-33136-1/</link>
<pubDate>Tue, 21 May 2013 03:29:35 MST</pubDate>
<description><![CDATA[LEESBURG, Va.  , May 21, 2013 /-&#160; RxAlly , a first-of-its-kind alliance of more than 22,000 pharmacies nationwide, announces today the publication of a white paper entitled Personalized Pharmacist Care: Healing America's Post-Reform Health Care System. The white paper highlights an unprecedented solution for improving patient health, reducing costs, and seeks public engagemen... ]]></description>
</item>
<item>
<title><![CDATA[Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Research-based-Pharmaceutical-Industry-Launches-Do-You-Mind-3F-Campaign-to-Fight-Mental-and-Neurological-Disorders-33135-1/</link>
<pubDate>Mon, 20 May 2013 10:20:05 MST</pubDate>
<description><![CDATA[GENEVA  , May 21, 2013 /-   &#160;     Campaign launched during World Health Assembly, where world's health ministers gather to address the large physical and economic costs of these disorders   Mental and neurological disorders (MNDs) affect 700 million people annually and account for 30 percent of global non-communicable disease (NCD) burden   'Do You Mind?' helps patients, fami... ]]></description>
</item>
<item>
<title><![CDATA[Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Volcano-to-Highlight-its-Physiology-Expansion-Efforts-at-EuroPCR-2013-33134-1/</link>
<pubDate>Mon, 20 May 2013 06:31:26 MST</pubDate>
<description><![CDATA[SAN DIEGO  , May 20, 2013 /-&#160;Volcano Corporation (NASDAQ:   VOLC ) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional F... ]]></description>
</item>
</channel>
</rss>